NEW YORK, July 26, 2017 -- Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit was commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of stock of Mallinckrodt Public Limited Company’s (“Mallinckrodt”) (NYSE:MNK), between November 25, 2014 and January 18, 2017 (“Class Period”), in Mallinckrodt’s voluntary and contributory employee benefit plans. If you contributed money in any of Mallinckrodt’s voluntary employee benefit plans and acquired Mallinckrodt ADSs as a result of such contributions, your rights may be affected.
The complaint alleges, among other claims, that Mallinckrodt’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to, among other things, the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
If you purchased or acquired Mallinckrodt stock in any of the Company’s employee benefit plans during the Class Period and wish to serve as a lead plaintiff you may move the Court no later than September 22, 2017; however you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Michael Klein, Esq. of SS&B at [email protected], telephone 212-687-7230 x147, or by fax to 212-490-2022.
SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. SS&B’s website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Italy Fines Apple €98.6 Million Over App Store Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



